ABCG2 and glioma: All observations and prediction data suggest a high mouse tolerance to MBL-II-141, and indicate that it would indeed be suitable for clinical development towards resistant cancer therapy or treatment of gliomas, which are limited by physiological barriers where the ABCG2 transporter plays a central role.